Standardized medicines are more reliable

Bedrocan is the only company in the world that has the proven capability of producing standardized whole-flower medical cannabis. Through a combination of stable plant genetics and proprietary, automated, high-tech production techniques, Bedrocan has the capacity to grow varieties that contain consistent levels of cannabinoids and terpenes every time.

Cannabinoids are the active ingredients that deliver the therapeutic effects of cannabis. Terpenes are the aromatic compounds that give cannabis varieties their distinctive smells and tastes, and there is also research suggesting that terpenes work synergistically with cannabinoids, modifying/enhancing their therapeutic effects in specific ways.

Standardization is the only method of ensuring that health professionals and patients can expect consistent therapeutic effect over time, allowing for accurate dosing, and proper monitoring of the product’s efficacy, safety and side effects. Only standardized products can be used for proper scientific research studies, because results can be compared over time and clear conclusions can be drawn.

Other cannabis producers may achieve a level of standardization in certain products by milling and blending varieties with different cannabinoid levels, but this process only creates equal levels of one or two target compounds (typically THC and/or CBD) – not the entire cannabinoid and terpene profile. Bedrocan can standardize cannabis plants down to the whole-flower level, with consistent cannabinoid and terpene content with the same rigour as traditional prescription medicines.

Bedrocan believes all medicines – cannabis included – should be standardized, and thereby, more reliable.

EQUAL Study:

Evaluating QUAlity of Life is the largest cannabis study of its kind, designed to determine how medical cannabis affects patients' overall quality of life. For more information please contact us.

Contact Us

Medical Advisory Board

The advisory board includes physicians specializing in pain management, psychiatry, medical oncology, and physical rehabilitation, as well as a PhD expert in medicinal cannabis and plant-based medicines. Each member has clinical and/or research experience in the use of cannabis for the management of symptoms associated with chronic health conditions.

Dr. Donald Abrams

Chief of the Hematology-Oncology Division at San Francisco General Hospital, Professor of Clinical Medicine at the University of California San Francisco, and one of the world’s foremost experts – as a researcher and clinician – in the medicinal uses of cannabis.

Dr. Karen Ethans

Director of the Spinal Cord Unit at Winnipeg Health Sciences Centre, and Associate Professor in the University of Manitoba, Department of Internal Medicine’s Section of Physical Medicine and Rehabilitation.

Dr. Marcia Gillman

is a palliative care specialist who works at Montreal’s Jewish General Hospital. Dr. Gillman is a Faculty Lecturer with McGill University’s Faculty of Medicine (Department of Family Medicine), and a founding director of Santé Cannabis, which is Quebec’s first clinic specializing in cannabis and cannabinoid medicine.

Dr. Martin Katzman

Clinic Director and Staff Psychiatrist at Toronto’s START Clinic (Stress, Trauma, Anxiety Rehabilitation and Treatment) for Mood and Anxiety Disorders, and a faculty member at the Northern Ontario School of Medicine (Laurentian University and Lakehead University) as well as in the Department of Psychiatry at the University of Toronto.

Dr. Alan Bell

Dr. Bell is a family physician and clinical researcher in Toronto, Canada. He is Assistant Professor in the Department of Family and Community Medicine, University of Toronto, and on the active staff of the Humber River Regional Hospital. He is a recipient of the Canadian College of Family Physicians Award of Excellence. Dr. Bell’s involvement in continuing medical education includes the development and presentation of many national projects. He has served as faculty and chair of countless committees and advisory boards dedicated to serving the common interests of the medical profession and the public.

He is past chair of the Canadian Cardiovascular Society Antiplatelet Guideline Committee, member of Thrombosis Canada Executive Council, the Canadian Stroke Network Professional Development Committee, Ontario Lung Association Asthma Advisory Committee and Peer Reviewer for the Canadian Medical Association Journal. His research, commentaries and letters have been presented and published internationally.

Arno Hazekamp

PhD, Head of Research and Development for Bedrocan BV, the official grower of medicinal cannabis in the Netherlands, whose PhD program at the Leiden-Amsterdam Center for Drug Research focused on the medicinal properties of the cannabis plant and its practical use in modern medicine, and who is a globally-recognized expert in the chemical analysis, quality control, and product development of medicinal cannabis.

Forgot your password?

New Customer? Sign up →